Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Zizzi, Antonio ^a   Montironi, Maria Alessandra ^a   Mazzucchelli, Roberta ^a   Scarpelli, Marina ^a   Lopez Beltran, Antonio ^b   Cheng, Liang ^c   Paone, Nicola ^a   Castellini, Paolo ^a   Montironi, Rodolfo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Universidad de Cordoba   (Spain)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Biological regulator; Chromatin remodeler DAXX; Urothelial carcinoma; Urothelium

Indexed keywords

DAXX PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ARTICLE; BLADDER TUMOR; CANCER GRADING; CARCINOMA IN SITU; CELL NUCLEUS; CHEMISTRY; CHROMATIN ASSEMBLY AND DISASSEMBLY; HUMAN; IMMUNOHISTOCHEMISTRY; NUCLEAR SIZE; PAPILLARY CARCINOMA; PATHOLOGY; PREDICTIVE VALUE; TUMOR INVASION; UROTHELIUM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; CELL NUCLEUS; CELL NUCLEUS SIZE; CHROMATIN ASSEMBLY AND DISASSEMBLY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84879810712     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-111     Document Type: Article

References (22)

1. Gårdmark T, Bladström A, Hellsten S, Malmström PU, Members of The Swedish National Bladder Cancer Registry Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol 2006, 40:276-282. 10.1080/00365590600744238, 16916767, Members of The Swedish National Bladder Cancer Registry.
2. Montironi R, Cheng L, Scarpelli M, Mazzucchelli R, Lopez-Beltran A. How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. Diagn Pathol 2011, 6:31. 10.1186/1746-1596-6-31, 3107770, 21473752.
3. Segersten MU, Edlund EK, Micke P, De la Torre M, Hamberg H, Edvinsson AE, Andersson SE, Malmström PU, Wester HK. A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer. BJU Int 2009, 104:1780-1785. 10.1111/j.1464-410X.2009.08674.x, 19522865.
4. Als AB, Dyrskjøt L, Von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen KM, Orntoft TF. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007, 13:4407-4414. 10.1158/1078-0432.CCR-07-0109, 17671123.
5. Birkhahn M, Mitra AP, Cote RJ. Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 2007, 7:1717-1727. 10.1586/14737140.7.12.1717, 18062746.
6. Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008, 4:71-83. 10.2217/14796694.4.1.71, 18241002.
7. Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, Zhou W, Wu W, Li Q. Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol 2012, 7:159. 10.1186/1746-1596-7-159, 3539897, 23173870.
8. Barbisan F, Mazzucchelli R, Santinelli A, Stramazzotti D, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. Int J Immunopathol Pharmacol 2008, 21:615-623.
9. Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Bartels H, Bartels PH, Alberts DS, Montironi R. Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis. Int J Immunopathol Pharmacol 2011, 24:489-497.
10. Campos EI, Reinberg D. New chaps in the histone chaperone arena. Genes Dev 2010, 24:1334-1338. 10.1101/gad.1946810, 2895192, 20595228.
11. Drané P, Ouararhni K, Depaux A, Shuaib M, Hamiche A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 2010, 24:1253-6125. 10.1101/gad.566910, 2885661, 20504901.
12. Hollenbach AD, McPherson CJ, Mientjes EJ, Iyengar R, Grosveld G. Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J Cell Sci 2002, 115:3319-3330.
13. Tang J, Agrawal T, Cheng Q, Qu L, Brewer MD, Chen J, Yang X. Phosphorylation of Daxx by ATM contributes to DNA damage-induced p53 activation. PLoS One 2013, 8:e55813. 10.1371/journal.pone.0055813, 3566025, 23405218.
14. De Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol 2012, 25:1033-1039. 10.1038/modpathol.2012.53, 3547622, 22575867.
15. Puto LA, Reed JC. Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylation. Genes Dev 2008, 22:998-1010. 10.1101/gad.1632208, 2335332, 18413714.
16. Ryo A, Hirai A, Nishi M, Liou YC, Perrem K, Lin SC, Hirano H, Lee SW, Aoki I. A suppressive role of the prolyl isomerase Pin1 in cellular apoptosis mediated by the death-associated protein Daxx. J Biol Chem 2007, 282:36671-36681. 10.1074/jbc.M704145200, 17938171.
17. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, De Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue C. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012, 36:173-184. 10.1097/PAS.0b013e3182417d36, 3261427, 22251937.
18. Zhang H, He J, Li J, Tian D, Gu L, Zhou M. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J 2013, 27:232-242. 10.1096/fj.12-215491, 23038753.
19. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31:89-97. 10.1016/j.tibs.2005.12.008, 16403636.
20. Herranz M, Esteller M. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets. Methods Mol Biol 2007, 361:25-62.
21. Rundlett SE, Carmen AA, Suka N, Turner BM, Grunstein M. Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature 1998, 392:831-835. 10.1038/33952, 9572144.
22. Vogelauer M, Wu J, Suka N, Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000, 408:495-498. 10.1038/35044127, 11100734.